Apeloa Pharmaceutical (SHE:000739) obtained a certificate of suitability from the European Union for the gabapentin active pharmaceutical ingredient, according to a Shenzhen bourse filing on Thursday.
The drug is used for the treatment of postherpetic neuralgia in adults and epilepsy in children.
The pharmaceutical company's shares fell nearly 2% during the afternoon trade.